All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, Syndax, Thermo Fisher Scientific, Kura Oncology, AbbVie, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group.
The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
The AML Hub held a virtual symposium on November 19, 2025, titled Understanding the differences between FLT3-ITD and -TKD mutations in AML: Implications for clinical practice. The symposium was chaired by Gail J. Roboz, with presentations from Roboz, Jorge Sierra, and Jorge Cortes, and ended with a panel Q&A discussion with live audience participation. Explore each session below:
During the recent AML Hub virtual symposium, Jorge Sierra, Hospital de la Santa Creu i Sant Pau, Barcelona, ES, presented the first session, titled “FLT3 mutations in AML: Types, prevalence, and clinical significance”.
During the recent AML Hub virtual symposium, Jorge Cortes, Georgia Cancer Center, Augusta, US, presented the second session, titled Comparing treatment options for patients with FLT3-ITD and -TKD mutations.
During the recent AML Hub virtual symposium, Gail J. Roboz, Weill Cornell Medicine, New York, US, presented the final session, titled Implications for clinical practice: Managing AML with FLT3-ITD and -TKD mutations.
The recent AML Hub virtual symposium, titled Understanding the differences between FLT3-ITD and -TKD mutations in AML: Implications for clinical practice, concluded with a panel Q&A discussion around treatment decisions for patients with FLT3-mutated acute myeloid leukemia (AML).
This educational resource is independently supported by Daiichi Sankyo. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.
Jorge Sierra
Jorge Cortes
Gail J. Roboz
